That means your entire consultation, prescription, and ongoing care can happen online
In a Phase 2 clinical trial published in the New England Journal of Medicine (Jastreboff et al., 2023), participants using retatrutide experienced up to 24% reduction in body weight over 48 weeks, significantly outperforming earlier GLP-1 agents
GHK-Cu affects over 4,000 human genes according to research, with particularly strong influences on genes related to tissue remodeling, antioxidant protection, and cellular regeneration
This action slows the rate at which your stomach empties food into the small intestine, creating a prolonged feeling of fullness
Clinical Evaluation & Lab Work: This is a non-negotiable element
For years, much of the clinical benefit of GLP-1 receptor agonists in MASH has been attributed primarily to weight loss